REACH (Reversing the Epidemic in Africa with Choices in HIV prevention, or MTN-034) is a study that seeks to understand the HIV prevention needs and preferences of adolescent girls and young women, who are among those at highest risk of HIV in sub-Saharan Africa.
Two different approaches will be evaluated in REACH -- the dapivirine vaginal ring, which is used for a month at a time; and an oral tablet called Truvada taken daily, a regimen often referred to as PrEP. The study will evaluate how adolescent girls and young women use these approaches and their preferences for either or both. REACH will also collect information on the safety of the dapivirine ring and daily PrEP.
The study will involve approximately 300 girls and young women ages 16-21 and will be conducted at five sites in Kenya, Uganda, South Africa and Zimbabwe.
Emavundleni (EMA) Clinical Research Site
14 Sonwabile Road
7750, South Africa
Tel: +27 21 650 5869
Wits Reproductive Health & HIV Institute (Wits RHI) Research Center
7 Esselen Street
2001, South Africa
Tel: +27 11 358 5424
Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration CRS
Upper Mulago Hill Road
Tel: +256 414-541044
Spilhaus Clinical Research Site
Zimbabwe National Family Planning Council
Harare Hospital Grounds, Highfield Road
Tel: +263-4-252299 / 7911374
KEMRI/CDC KISUMU Clinical Research Site
Off Kakamega Road,
P.O. Box 1578-40100
Tel: +25 47 39246650
or +25 47 99946432
Watch this video if you want to learn more about REACH:
REACH is a study of the Microbicide Trials Network, and is funded by the U.S. National Institutes of Health.